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ABSTRACT
The growth-promoting effect of continuous GH treatment was eval-
uated over 5 yr in 79 children with short stature (height SD score, less
than 21.88) born small for gestational age (SGA; birth length SD score,
less than 21.88). Patients were randomly and blindly assigned to 1
of 2 GH dosage groups (3 vs. 6 IU/m2 body surfacezday). GH deficiency
was not an exclusion criterium. After 5 yr of GH treatment almost
every child had reached a height well within the normal range for
healthy Dutch children and in the range of their target height SD
score. Only in children who remained prepubertal during the study
period was the 5-yr increase in height SD score (HSDS) for chrono-
logical age significantly higher in the study group receiving 6 com-
pared to 3 IU GH/m2zday. Remarkably, the 5-yr increment in HSDS
for chronological age was not related to spontaneous GH secretion,
maximum GH levels after provocation, or baseline insulin-like growth
factor I levels. GH treatment was associated with an acceleration of
bone maturation regardless of the GH dose given. The HSDS for bone
age and predicted adult height increased significantly. GH treatment
was well tolerated.
In conclusion, our 5-yr data show that long term continuous GH
treatment at a dose of 3 or 6 IU/m2zday in short children born SGA
results in a normalization of height during childhood followed by
growth along the target height percentile. (J Clin Endocrinol Metab
84: 3064–3070, 1999)
SHORT STATURE in children born small for gestationalage (SGA) is a well known phenomenon. Although
postnatal catch-up growth occurs in most of the SGA new-
borns, about 15% of these children fail to show catch-up
growth (1, 2). They present with a height deficit during
childhood that in almost all cases results in short adult stat-
ure (3–5). The mechanism of the stunted postnatal growth in
short children born SGA is poorly understood. It has been
previously shown that disturbances in the GH/insulin-like
growth factor I (IGF-I) axis may account for some of the
growth retardation; up to 60% of the short children born SGA
have GH secretory abnormalities and/or reduced levels of
IGFs (6–12). GH treatment in these children has been ex-
plored from the early 1970s (13, 14). Initial data were dis-
appointing, probably due to the low dose and frequency of
GH administration. Recent short term studies have shown
that daily administration of recombinant human GH therapy
in varying dosages accelerates growth significantly in short
children born SGA (7, 15–22).
To assess whether GH treatment will also improve linear
growth over the long term as well as adult height, we started
a randomized, double blind, dose-response multicenter trial
with continuous GH treatment in 79 prepubertal children
with short stature born SGA. We now report a 5-yr analysis
comparing the effects of 2 doses of GH (3 vs. 6 IU/m2 body
surfacezday).
Subjects and Methods
Study group
Seventy-nine prepubertal short children born SGA were included
after meeting the following criteria: 1) birth length sd score below 21.88
(that is, less than the third percentile) for gestational age according to the
standards of Usher and McLean (23); 2) chronological age (CA) between
3–11 yr in boys and 3–9 yr in girls at the start of the study; 3) height sd
score for CA (HSDSCA) below 21.88 according to Dutch references (24);
4) height velocity sd score for CA (HVSDS) of zero or less (24, 25), to
exclude children presenting spontaneous catch-up growth; 5) prepu-
bertal stage, defined as Tanner breast stage I for girls and testicular
volume less than 4 mL for boys (26); 6) uncomplicated neonatal period,
that is without signs of severe asphyxia (defined as an Apgar score ,3
after 5 min), without sepsis neonatorum and without long term com-
plications of respiratory ventilation, such as bronchopulmonary dys-
plasia. Exclusion criteria were endocrine or metabolic disorders, chro-
mosomal disorders, growth failure caused by other disorders or
syndromes (emotional deprivation, severe chronic illness, or chondro-
dysplasia), and previous or present use of drugs that could interfere with
GH treatment. Patients with Silver-Russell syndrome (SRS), however,
were included in this study. GH deficiency was not an exclusion
criterium.
Four centers in The Netherlands participated in the study. The study
was approved by the ethics committee of each participating center.
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Written informed consent was obtained from the parents or custodians
of each child.
Study design
Before GH treatment, 40 of the 79 children underwent a 24-h plasma
GH profile, as described previously (6). To stratify for the spontaneous
GH secretion during the 24-h GH profile, the total group of 79 children
was divided into 3 groups: normal profile, GH-insufficient profile (area
under the curve, ,90 mg/Lz24 h; mean GH, ,2.0 mg/L), and no profile
performed. After stratification for spontaneous GH secretion during the
24-h GH profile and for CA, all children were randomly and blindly
assigned to 1 of 2 GH dosage groups: group A, 3 IU/m2 body
surfacezday; or group B, 6 IU/m2 body surfacezday (;0.1 or 0.2 IU/
kgzday, respectively). Biosynthetic GH (r-hGH Norditropin, Novo Nor-
disk A/S, Bagsvaerd, Denmark) was given sc once daily at bedtime with
a pen injection system (Nordiject 24). Every 3 months the total GH dose
was adjusted to the calculated body surface. The study was kept double
blind by using an equal volume of a reconstituted preparation. Criteria
to discontinue GH treatment were height velocity (HV) below 0.5 cm
over the last 6 months and/or bone age of 15 yr or more for girls and
of 16.5 yr or more for boys.
Growth evaluation
Height (H) was measured at baseline and subsequently every 3
months, according to the method of Cameron (27) using a Harpenden
stadiometer (Holtain, Ltd., Crymmyth, UK). Four measurements per
visit were made by two trained observers (W.d.W. and later on Th.S.),
and the mean was used for the analysis. Height was expressed as the sd
score for CA (HSDSCA) (24). Target height (TH) was adapted from Dutch
reference data with the addition of 3 cm for a secular trend: 1/2 3 (Hfather
1 Hmother 1 12) 1 3 for boys and 1/2 3 (Hfather 1 Hmother 2 12) 1 3 for
girls (24). TH and body mass index (BMI) were expressed as sd scores
using Dutch references (24). Bone age (BA) was determined by one
investigator (Th.S.) according to Tanner and Whitehouse radius, ulna,
and short bones score (BARUS) (28). Bone maturation was expressed as
the ratio of the change in BA to the change in CA (DBA/DCA). The HSDS
for BA (HSDSBA) and adult height prediction according to the Tanner
and Whitehouse prediction method (TW2) (28) were used as indexes of
adult height prognosis. Pubertal stages were assessed by the same two
investigators according to the method of Tanner (26), using an or-
chidometer in boys.
Biochemical parameters
Before treatment, a standard arginine tolerance test was performed
(6). A standard oral glucose tolerance test (OGTT) was performed at
baseline and after 1 yr of GH treatment (29). Additional blood samples
were taken at the start of the study and subsequently every year for
determination of IGF-I and hemoglobin A1c levels. IGF-binding pro-
tein-3 (IGFBP-3) was determined at start of the study and after the first
and second years and after the fifth year of GH treatment. After cen-
trifugation, all samples were frozen (220 C) until assayed.
Hormone assays
The RIA measurements of plasma GH, IGF-I, IGFBP-3, and insulin
were performed as described previously (30–33). All measurements
were performed in the same laboratories. As levels of both IGF-I and
IGFBP-3 are dependent on age and sex, values were transformed to sd
scores using reference values for healthy children determined in the
same laboratory (34).
Statistical analyses
Results are expressed as the mean 6 sd, unless indicated otherwise.
Differences between groups were tested using Student’s t tests. Differ-
ences between points in time were tested by paired Student’s t tests. To
study the relation between the growth response variables (increment in
HSDSCA after 5 yr) and baseline parameters, multiple linear regression
analyses, adjusted for GH dosage group, were performed. For each
possible predictive factor, separate analyses were performed. Possible
predictive baseline factors were: CA, BARUS, BA delay (CA 2 BA), TH
sd score, IGF-I sd score, pretreatment HVSDS, maximum GH value
during the GH provocation test, and the characteristics of the 24-h GH
profiles established at the start of the study (6). A subgroup analysis of
prepubertal growth was performed in the group of children who re-
mained prepubertal during the entire study period. Girls with Tanner
breast stage I and boys with a testis volume of 6 mL or less during the
5-yr study period were included in this analysis of prepubertal growth.
P , 0.05 was considered significant.
As the study remains double blind until final height is reached,
statistical analysis was performed by an independent statistician (P.M.);
therefore, data are only expressed as the mean 6 sd.
Results
Clinical data, growth, and bone maturation
Table 1 lists the baseline clinical data of the 79 children.
Both GH dosage groups had similar initial characteristics.
Seven children had SRS. Five children dropped out of the
study for the following reasons. Three children were no
longer motivated to inject GH daily after 15, 45, and 51
months of GH treatment, respectively, despite ongoing
catch-up growth with GH treatment in 2 of the 3 children.
One girl dropped out of the study because of treatment for
early puberty after 27 months of GH treatment. In 1 boy, GH
treatment was discontinued after 27 months because of signs
of GH insensitivity. During GH treatment his IGF-I levels
and HV did not increase despite good compliance with treat-
ment. As these 5 children were lost to follow-up after dis-
continuation of GH, their data were not included in the
analysis.
Figure 1 shows the height at baseline as well as the height
after 5 yr of GH treatment. During the 5-yr study period,
onset of puberty was observed in 47 of the 74 children. The
mean CA at the onset of puberty did not differ between the
GH dosage groups (in girls, 10.5 6 0.9 vs. 11.0 6 1.1 yr; in
boys, 11.9 6 0.9 vs. 11.6 6 0.6) and was apparently within the
normal range. One male adolescent discontinued GH treat-
ment after 54 months because of satisfaction with the height
achieved (165.3 cm). All other children were still growing
and receiving GH treatment. As the design of the study is still
double blind, in these figures no separate growth diagrams
were made for the 2 GH dosage groups. After 5 yr, almost
every child had achieved a height well within the normal
range for healthy Dutch children.
Figure 2 shows the HSDSCA at baseline and throughout the
5-yr study period. After 5 yr of GH treatment, the mean
HSDSCA in both GH dosage groups have significantly in-
creased compared to baseline values (P , 0.001) and in
TABLE 1. Baseline clinical data
Group A
(3 IU/m2 z day; n 5 41)
Group B
(6 IU/m2 z day; n 5 38)
Male/female 31/10 21/17
Gestational age (weeks) 37.3 6 3.2 36.0 6 4.1
Birth length SD score 23.6 6 1.4 23.7 6 1.7
Birth wt SD score 22.6 6 1.2 22.6 6 1.0
Chronological age (yr) 7.3 6 2.1 7.2 6 2.4
Bone age (RUS; yr) 6.6 6 2.4 6.7 6 2.9
Ht SD scoreCA 23.0 6 0.7 23.1 6 0.7
Ht velocity SD score 20.7 6 1.1 21.2 6 1.3
Target ht SD score 21.0 6 0.9 20.5 6 0.9
Values are the mean 6 SD.
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conformity with the target height sd score. Although the 5-yr
increase in HSDSCA was higher in group B (2.6 6 0.9) than
in group A (2.2 6 0.6), the difference was not statistically
significant (P 5 0.057). The increment in HSDSCA was not
different between the seven children with SRS and those
without SRS (data not shown).
Figure 3 shows the DBA/DCA ratio per yr throughout the
5-yr study period. The mean DBA/DCA ratio per yr was
significantly higher than 1 for both GH dosage groups (1.4 6
0.2 and 1.3 6 0.2, respectively; P , 0.001). No significant
difference in bone maturation was found between the two
GH dosage groups. At baseline, mean BARUS retardation was
0.6 6 1.0 yr, whereas after 5 yr of GH treatment, mean BARUS
was advanced by 1.0 6 1.1 yr.
After 5 yr of GH treatment, HSDSBA increased significantly
compared to baseline (P # 0.001). The increase was signifi-
cantly higher in group B (from 22.4 6 1.0 to 1.2 6 0.8)
compared to that in group A (from 22.1 6 1.1 to 1.5 6 0.8;
P 5 0.004).
In the subanalysis on prepubertal growth (n 5 23 in group
A; n 5 16 in group B), the increment in HSDSCA was sig-
nificantly increased in both GH dosage groups (P , 0.001;
Fig. 4). The increase in HSDSCA was significantly higher in
group B (3.30 6 0.73) than in group A (2.35 6 0.51; P , 0.001).
The mean DBA/DCA ratio per yr was significantly higher
FIG. 2. Mean (6SD) HSDSCA for both GH dosage groups during 5 yr
of GH treatment. The TH SD score (61 SD) is indicated.
FIG. 3. Mean (6SD) ratio [DBA (years)/DCA (years)] per yr for both
GH dosage groups during 5 yr of GH treatment.
FIG. 1. Individual heights at start of the study and after 5 yr of GH
treatment. Reference curves for healthy Dutch children (P3, P10, P50,
P90, and P97) are given.
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than 1 for both GH dosage groups (1.39 6 1.17 and 1.37 6
0.22, respectively; P , 0.001), without significant differences
between the two groups. HSDSBA increased significantly
compared to baseline (P , 0.05). The increase in HSDSBA was
significantly higher in group B (from 22.06 6 1.17 to 20.88 6
0.93) compared to that in group A (from 21.86 6 1.11 to
21.49 6 0.89; P 5 0.02). The increase in predicted adult
height after 5 yr of GH treatment was 9.1 6 2.8 cm in group
A and 14.0 6 5.5 cm in group B, being significantly increased
compared to baseline in both GH dosage groups (P , 0.005)
and significantly higher in group B than in group A (P 5
0.02).
BMI
At baseline, the BMI sd score (BMI-SDS) was 21.2 6 1.3
in group A and 21.2 6 1.1 in group B, being significantly
lower than zero (P , 0.001). After 5 yr of GH treatment,
BMI-SDS was significantly increased to 20.3 6 1.2 in group
A and to 20.2 6 0.8 in group B (P , 0.001). The increase in
BMI-SDS was not significantly different between the two GH
dosage groups.
GH, IGF-I, and IGFBP-3
The results of the 24-h plasma GH profiles at baseline have
been described previously (6). The mean 6 sd maximum
serum GH concentration during the arginine tolerance test at
baseline was not significantly different between the two GH
dosage groups (11.2 6 6.3 vs. 14.0 6 6.3 mg/L). In 27 children,
the maximal GH peak was below 10 mg/L.
Table 2 shows the IGF-I and IGFBP-3 sd score at baseline
and during 5 yr of GH treatment. The baseline IGF-I sd score
was significantly lower than zero. During GH treatment, the
IGF-I sd score was significantly higher than baseline at each
point in time for both GH dosage groups. The IGF-I sd score
was significantly higher in group B compared to group A
during the first 3 yr. Thereafter, this difference was no longer
statistically significant. The mean baseline IGFBP-3 sd score
was significantly lower than zero. During the first year of GH
treatment, the IGFBP-3 concentrations normalized, and after
5 yr, the IGFBP-3 sd score was significantly higher than zero
for both GH dosage groups. The IGFBP-3 sd score after 5 yr
of GH treatment was not significantly different between
groups A and B.
Predictors for growth response
After adjustment for GH dosage group, the 5-year increase
in HSDSCA correlated negatively with baseline CA (b 5
20.216; P , 0.001) and baseline BARUS (b 5 20.173; P ,
0.001). The 5-yr change in HSDSCA was not significantly
related to the TH sd score, baseline BA delay, pretreatment
HVSDS, baseline IGF-I sd score, mean maximal plasma GH
response during arginine tolerance test, or characteristics of
the 24-h GH profiles established at the start of the study (6).
In addition, no difference in the 5-yr increment in HSDSCA
was found between the children with GH deficiency and
those with normal GH levels.
Safety
Treatment was well tolerated, and no adverse events were
detected that were considered to be drug related. In both GH
dosage groups, the mean fasting glucose level and area under
the curve for glucose during OGTT did not significantly
change during 1 yr of GH treatment compared to baseline
values. In contrast, the mean fasting insulin levels increased
significantly in both GH dosage groups after 1 yr of GH
treatment, from 6.4 to 7.6 mU/L and from 4.9 to 8.4 mU/L
for groups A and B, respectively (P , 0.01). In addition, the
area under the curve for insulin during OGTT was signifi-
cantly higher after 1 yr of GH treatment compared to the
baseline (P , 0.001), from 1433 at baseline to 2101 mU/Lz1
h after 1 yr for group A and from 1161 to 2634 mU/Lz1 h for
group B, however, without a significant difference between
the two GH dosage groups. Hemoglobin A1c levels remained
within the normal range, and none of the children developed
diabetes mellitus.
Discussion
Our study shows that long term continuous GH treatment
(3 vs. 6 IU/m2zday) in children with short stature born SGA
results in a normalization of height during childhood, fol-
FIG. 4. Mean (6SD) HSDSCA for both GH dosage groups during 5 yr
of GH treatment in the children who remained prepubertal during the
study period. The TH SD score (61 SD) is indicated.
TABLE 2. Mean (6SD) IGF-I and IGFBP-3 SD scores
Group A
(3 IU/m2 z day)
Group B
(6 IU/m2 z day)
IGF-I SD score
Baseline 21.2 6 1.2a 20.9 6 1.0a
1 yr 1.2 6 1.1a 1.9 6 1.1a,b
2 yr 1.2 6 1.0a 1.9 6 1.2a,c
3 yr 1.4 6 1.0a 2.0 6 1.2a,c
4 yr 1.8 6 0.8a 2.0 6 1.2a
5 yr 1.7 6 0.7a 2.0 6 0.9a
IGFBP-3 SD score
Baseline 21.7 6 1.3a 21.3 6 1.1a
1 yr 0.2 6 1.2 0.5 6 1.1d
2 yr 0.0 6 1.2 0.2 6 1.0
5 yr 1.0 6 0.8a 1.2 6 1.0a
a Significantly different from zero, P , 0.001.
b Significantly higher in the group receiving 6 than in the group
receiving 3 IU/m2 z day, P 5 0.01.
c Significantly higher in the group receiving 6 than in the group
receiving 3 IU/m2 z day, P , 0.05.
d Significantly different from zero, P 5 0.021.
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lowed by growth along the target height percentile. The
difference in gain in HSDSCA between the GH dosage groups
was not statistically significant. Only in children who re-
mained prepubertal during the study was the mean gain in
HSDSCA after 5 yr of GH treatment significantly greater in
those treated with 6 compared to 3 IU/m2zday. Both GH
dosage groups reached their target height sd score well
within 5 yr of GH treatment, indicating that long term GH
treatment with a lower GH dose of 3 IU/m2zday is also able
to normalize the height of short children born SGA.
Most controlled trials have shown a beneficial effect of GH
treatment over a period of 2–3 yr in comparison with a
randomized untreated group of children born SGA for 1 or
2 yr. The untreated children did not show any spontaneous
catch-up growth, indicating that they are destined to remain
short (18, 20, 21). For our long term study, a randomized
controlled trial with an untreated group until adult height
was reached was considered unethical by several ethics com-
mittees. Therefore, a dose-response design comparing two
GH dosages (3 and 6 IU/m2zday) was chosen to evaluate the
long term use of continuous GH treatment.
Our 5-yr results consolidate the previously described ef-
fects of short term GH treatment in short children born SGA
(18–22). In the 3-yr study reported by Boguszewski et al.,
daily GH dosages (3 and 6 IU/m2) similar to those in our
study were used. Interestingly, the GH dose-dependent 3-yr
increase in HSDSCA in prepubertal children was almost iden-
tical in both studies (21). A meta-analysis of four European
trials showed that the 4-yr growth response was similar
between continuous GH use (3 IU/m2zday for 4 yr) and
discontinuous GH use (6 IU/m2zday for 2 yr, followed by 2
yr without GH) (22), suggesting that the cumulative GH dose
received and not the daily GH dose determines the growth
response. All studies demonstrate that GH treatment induces
an acceleration in linear growth in short children born SGA.
In addition, our 5-yr study shows that continuous GH treat-
ment can normalize height and is followed by a persistent
growth within the normal height range.
Comparing our growth results with those of other GH-
treated patient groups receiving long term GH treatment, the
gain in height in short children born SGA is comparable with
that in GHD patients with a GH dose that is slightly higher
than the conventional GH dose (2 IU/m2zday) (35).
In some previous short term studies and in the present
study, bone maturation was accelerated compared to that in
untreated short children born SGA and compared to healthy
children, respectively (18, 20, 22). However, it was remark-
able that during the 5-yr treatment period, bone maturation
in the total group as well as in the children who remained
prepubertal during the study period appeared to be inde-
pendent of the given GH dose, whereas no progressive ac-
celeration of bone maturation was found. Previous reports
have demonstrated a spontaneous acceleration of bone mat-
uration from the age of 6–10 yr in untreated children with
short stature born SGA (3, 36, 37). Therefore, the acceleration
of bone maturation seen in GH-treated short children born
SGA may be partly explained by the effects of GH treatment,
but may also be explained by the spontaneous acceleration
of bone maturation observed in untreated SGA children.
Data on final height are very limited. Therefore, an indi-
cation of final height is often given by the change in HSDSBA
and the predicted adult height, according to the Tanner and
Whitehouse prediction method, during GH treatment. In our
study, HSDSBA and predicted adult height increased signif-
icantly after 5 yr of GH treatment, in conformity with the
results described in short term studies (20, 22). Thus, the gain
in height outweighs the faster bone maturation. However,
we realize that both prediction methods have limitations;
therefore, data on adult height have to substantiate our re-
sults. Only 2 studies reported data on final height in rela-
tively small numbers of patients (38, 39). One study reported
data from a pharmaceutical registration database showing
that 16 SGA patients, treated with GH at a median daily GH
dose of approximately 3 IU/m2 until near adult height,
achieved an adult stature that was 1.0 sd score greater than
the pretreatment HSDSCA (38). However, in these patients
the median age at start of treatment was 12.7 yr. Preliminary
data from the study by Albanese et al. demonstrated that in
12 GH-treated children with short stature born SGA, GH
treatment with approximately 4 IU/m2zday starting at a
mean age of 7.6 yr significantly improved final height. Al-
though HSDSBA did not improve throughout the study, the
HSDSCA had increased from 22.9 at baseline to 21.5 at final
height (39).
Some studies reported earlier onset of puberty in un-
treated short children born SGA (36, 37). The question arose
as to whether GH could further advance the timing of pu-
berty and consequently reduce the growth period. In our
study the mean pubertal onset seemed not to be advanced by
GH treatment (girls, 10.8 yr; boys, 11.8 yr). However, longer
follow-up is required to establish whether all of our children
will start puberty at an appropriate age and whether the
overall duration of puberty is altered.
As described in other studies, the variability in growth
response to GH treatment was considerable. For that reason,
we looked for clinical predictors of the growth response to
GH treatment. The increase in HSDSCA over 5 yr of treatment
was negatively related to baseline CA and BA; the younger
the child at baseline, the better the 5-yr increase in HSDSCA.
In contrast, neither the height of the parents, the pretreatment
HV, nor the baseline BA retardation were related to the 5-yr
increment in height.
The etiology underlying the insufficient spontaneous
catch-up growth in short children born SGA is poorly un-
derstood. Findings in previous studies (6–12) and in our
study suggest that disturbances in the GH/IGF-I axis play a
role in the absence of spontaneous catch-up growth. How-
ever, before treatment, we found no clear relation between
the GH secretory status and spontaneous growth (6). To
study the relation between the baseline parameters of the GH
secretion status and the growth response to GH treatment,
we included, in contrast to other prospective studies, patients
regardless of their GH secretion. We found that the maxi-
mum GH levels during the provocation tests before the start
of the GH treatment were not significantly related to the
growth response. Two previous studies also found no dif-
ferences in growth response to GH treatment between SGA
children who were GH deficient and those who were not (35,
40). In addition, our study showed that neither the IGF-I
levels at baseline nor the GH levels during the 24-h plasma
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GH profile test were significantly related to the growth re-
sponse. Thus, although the stunted growth in short stature
children born SGA may be partly explained by disturbances
in the GH/IGF-I axis, the growth-promoting effect of GH
treatment at a dose of 3–6 IU/m2zday seems to be indepen-
dent of the baseline GH/IGF-I status.
It is well known that many short children born SGA are
lean and have a lack of appetite. In the present study, we did
not systematically investigate a possible change in the ap-
petite of the children. Several parents, however, mentioned
that the children had better appetite and food intake after the
start of the GH treatment. Although we do not know the
natural development of body mass in short children born
SGA during childhood, it is remarkable that the normaliza-
tion of height during GH treatment was accompanied by a
normalization of the BMI. We may speculate that the anabolic
effect of GH treatment has a positive influence on the food
intake of the child and that this plays an additional role in the
catch-up growth of short children born SGA.
Our study showed that the height gain after 5 yr of GH
treatment with 6 IU/m2zday was only statistically significant
higher than that after treatment with 3 IU/m2zday in the
children who remained prepubertal during the study period.
In addition, this difference was relatively modest, suggesting
that near-maximal GH effects in SGA children are reached in
this dose range. Follow-up until adult height is needed to
assess whether the higher GH dose results in a significantly
better improvement of adult height. Therefore, we will con-
tinue our double blind, dose-response study until all children
have attained adult height.
In conformity with other studies (18–22), tolerance to GH
treatment was good. No adverse events were detected that
were GH related. In our study, 1-yr GH treatment resulted
in a significant rise in insulin levels, with normal glucose and
glycosylated hemoglobin levels. SGA has been reported to be
associated with an impairment in insulin sensitivity and with
noninsulin-dependent diabetes mellitus in later life (41, 42).
Further studies on the effects of long term GH treatment on
carbohydrate metabolism are underway.
The most important aim of GH treatment in short children
born SGA is a normalization of height and, consequently, an
improvement of the psychosocial burden of being small in
childhood as well as in adulthood. A 2-yr psychosocial eval-
uation in the children of our study showed a beneficial effect
on behavioral and emotional problems and on the self-con-
cept of the children (43, 44). Further psychosocial research
will be performed to confirm this improvement.
In conclusion, our 5-yr data show that long term contin-
uous GH treatment (3 or 6 IU/m2zday) in short children born
SGA results in a normalization of height and subsequent
growth along the TH percentile. The increase in height ap-
pears to be independent of the baseline GH/IGF-I status.
Adult height prognosis and height sd score for BA increased
significantly despite acceleration of bone maturation. The
difference in growth response between the children receiving
6 IU/m2 daily and those receiving 3 IU/m2 was small and
was only significant in the children who remained prepu-
bertal during the study. Further studies should be directed
at optimizing GH modalities, at establishing adult height
results and long term safety data, and at determining the
predictors indicating the small children born SGA who will
benefit most from GH treatment.
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